Table 4. Transfusion outcomes for... | American Society of Hematology

Table 4.

Transfusion outcomes for studies grouped by baseline Hb levels

Citation	Transfusion trigger or mean Hb at transfusion^4-150	Baseline Hb	Study arm	No.enrolled	No.evaluable	EPO dose, U/kg/week		% transfused	P	Difference in % transfused (controlEpo)	RBC units per patient ± SD	P	RBC units per patient per 4 weeks	Difference in RBC units per patient per 4 weeks (controlEpo)
Citation	Transfusion trigger or mean Hb at transfusion^4-150	Baseline Hb	Study arm	No.enrolled	No.evaluable	Start	Final	% transfused	P	Difference in % transfused (controlEpo)	RBC units per patient ± SD	P	RBC units per patient per 4 weeks
Mean/median baseline Hb no higher than 10 g/dL, adult patients
Silvestris et al¹¹	NA	NS^4-151	Control	24	22	0
		NS^4-151	Epoetin	30	27	450	900
Oberhoff et al¹⁴	NA	10.3^‡	Control	110	88	0		40.9			0.6		0.6
		9.6^‡	Epoetin	117	101	∼ 450		25.7	^4-153	15.2	0.5	.044	0.5	0.1
Case et al⁹	8.2	9.8	Control	76	74	0		36.8^4-155			1.6 ± 0.3		0.8
	8.2	9.5	Epoetin	81	79	450		28.6^4-155	NS^4-154	8.5^4-155	0.9 ± 0.3	NS	0.5	0.3
Henry et al¹²	8.5	9.5	Control	65	61	0		68.9			4.0 ± 0.8		2.0
	8.2	9.8	Epoetin	67	64	450		53.1	NS	15.8	4.0 ± 0.9	NS	2.0	0
Cascinu et al¹⁰	8.0	8.7	Control	50	49	0		57.1			1.8		0.8
		8.6	Epoetin	50	50	300		20.0	.01	37.1	0.3	.01	0.1	0.7
Kurz et al¹³	8.0	9.85	Control	12	12	0		66.7			3.6		1.2
		9.88	Epoetin	23	23	450	900	21.7	.009	45.0	1.4		0.5	0.7
Littlewood et al¹⁵	NA	9.7	Control	124	115	0		35.7^4-155
Littlewood et al¹⁵	NA	9.9	Epoetin	251	244	450	900	23^4-155	.0168	12.7^4-155
Mean/median baseline Hb no higher than 10 g/dL, pediatric patients
Varan et al⁶¹	6.0	8.48	Control	17	17	0		47.1
		8.5	Epoetin	17	17	450		5.9	.008	41.2
Leon et al⁶⁰	6.0	9.5	Control	25	25	0		96			3.6		1.2
		9.8	Epoetin	25	25	450		16	<.001	80.0	0.3	<.001	0.1	1.1
Porter et al⁴⁰	8.0	9.4^‡	Control	12	10	0		100			13.0^‡		3.3
		9.7^‡	Epoetin	12	10	450	900	90	NS	10.0	4.5^‡	.01	1.1	2.2
Mean/median baseline Hb between 10 and 12 g/dL, adult patients
Markman et al²⁰	8.0	11.1^‡	Control	46	40	0		22.5
		11.5^‡	Epoetin	17	16	350		6.3	NS	16.2
Dusenbery et al²²	9.5	11.1^‡	Control	61	61	0		6.6
Dusenbery et al²²	9.5	10.3^‡	Epoetin	15	15	1000	500	0.0		6.6
Lavey and Dempsey²¹	NA	11.8	Control	20	20	0
Lavey and Dempsey²¹	NA	11.9	Epoetin	20	20	900	450
Wurnig et al²⁴	8.5	10.5	Control	14	14	0		100			8.4		1.7
		11	Epoetin	16	15	1200		53.3	NS	46.7	2.1	<.01	0.4	1.3
Henke et al²³	NA	12.3	Control	11	11	0
		10.9	Epoetin 1	19	19	450
		11.4	Epoetin 2	14	14	900
Quirt et al²⁶	NA	10.7^4-159	Control	28	27	0		29.6			0.7
		10.9^4-159	Epoetin	28	27	450	900	14.8	NS^4-154	14.8	0.2
ten Bokkel Huinink et al²⁵	9.7	11.8^‡	Control	34	33	0		39.4			1.2		0.2
ten Bokkel Huinink et al²⁵	9.7	12.0^‡	Epoetin 1	46	45	450	225	4.4	^4-153	35.0	0.3		0.1	0.1
		11.6^‡	Epoetin 2	42	42	900	450	14.3	^4-153	25.1	0.4		0.1	0.1
Mean/median baseline Hb no lower than 12 g/dL, adult patients
Gamucci et al⁶³	NA	12.7	Control	17	17	0
		12.2	Epoetin	21	21	450
Sweeney et al⁶²	NA	10.7	Control	24	24	0
		12.1	Epoetin	24	22	1000	500
Del Mastro et al⁶⁴	8.0	13.1	Control	31	31	0		6.5
Del Mastro et al⁶⁴	8.0	13	Epoetin	31	31	450		0	NS^4-154	6.5
Thatcher et al²⁷	8.5	13.4^‡	Control	44	44	0		59.1			6.1		0.9
	8.6	13.7^‡	Epoetin 1	42	42	450	225	45.2	<.05	13.9	3.8	< .01	0.6	0.3
	8.0	13.6^‡	Epoetin 2	44	44	900	450	20.5	<.001	38.6	2.1	< .001	0.3	0.6
Welch et al⁶⁵	8.5	12.8	Control	15	15	0		53.3			5.4
	8.3	13	Epoetin	15	15	900	450	26.7	NS	26.6	4.0	NS

Citation	Transfusion trigger or mean Hb at transfusion^4-150	Baseline Hb	Study arm	No.enrolled	No.evaluable	EPO dose, U/kg/week		% transfused	P	Difference in % transfused (controlEpo)	RBC units per patient ± SD	P	RBC units per patient per 4 weeks	Difference in RBC units per patient per 4 weeks (controlEpo)
Citation	Transfusion trigger or mean Hb at transfusion^4-150	Baseline Hb	Study arm	No.enrolled	No.evaluable	Start	Final	% transfused	P	Difference in % transfused (controlEpo)	RBC units per patient ± SD	P	RBC units per patient per 4 weeks
Mean/median baseline Hb no higher than 10 g/dL, adult patients
Silvestris et al¹¹	NA	NS^4-151	Control	24	22	0
		NS^4-151	Epoetin	30	27	450	900
Oberhoff et al¹⁴	NA	10.3^‡	Control	110	88	0		40.9			0.6		0.6
		9.6^‡	Epoetin	117	101	∼ 450		25.7	^4-153	15.2	0.5	.044	0.5	0.1
Case et al⁹	8.2	9.8	Control	76	74	0		36.8^4-155			1.6 ± 0.3		0.8
	8.2	9.5	Epoetin	81	79	450		28.6^4-155	NS^4-154	8.5^4-155	0.9 ± 0.3	NS	0.5	0.3
Henry et al¹²	8.5	9.5	Control	65	61	0		68.9			4.0 ± 0.8		2.0
	8.2	9.8	Epoetin	67	64	450		53.1	NS	15.8	4.0 ± 0.9	NS	2.0	0
Cascinu et al¹⁰	8.0	8.7	Control	50	49	0		57.1			1.8		0.8
		8.6	Epoetin	50	50	300		20.0	.01	37.1	0.3	.01	0.1	0.7
Kurz et al¹³	8.0	9.85	Control	12	12	0		66.7			3.6		1.2
		9.88	Epoetin	23	23	450	900	21.7	.009	45.0	1.4		0.5	0.7
Littlewood et al¹⁵	NA	9.7	Control	124	115	0		35.7^4-155
Littlewood et al¹⁵	NA	9.9	Epoetin	251	244	450	900	23^4-155	.0168	12.7^4-155
Mean/median baseline Hb no higher than 10 g/dL, pediatric patients
Varan et al⁶¹	6.0	8.48	Control	17	17	0		47.1
		8.5	Epoetin	17	17	450		5.9	.008	41.2
Leon et al⁶⁰	6.0	9.5	Control	25	25	0		96			3.6		1.2
		9.8	Epoetin	25	25	450		16	<.001	80.0	0.3	<.001	0.1	1.1
Porter et al⁴⁰	8.0	9.4^‡	Control	12	10	0		100			13.0^‡		3.3
		9.7^‡	Epoetin	12	10	450	900	90	NS	10.0	4.5^‡	.01	1.1	2.2
Mean/median baseline Hb between 10 and 12 g/dL, adult patients
Markman et al²⁰	8.0	11.1^‡	Control	46	40	0		22.5
		11.5^‡	Epoetin	17	16	350		6.3	NS	16.2
Dusenbery et al²²	9.5	11.1^‡	Control	61	61	0		6.6
Dusenbery et al²²	9.5	10.3^‡	Epoetin	15	15	1000	500	0.0		6.6
Lavey and Dempsey²¹	NA	11.8	Control	20	20	0
Lavey and Dempsey²¹	NA	11.9	Epoetin	20	20	900	450
Wurnig et al²⁴	8.5	10.5	Control	14	14	0		100			8.4		1.7
		11	Epoetin	16	15	1200		53.3	NS	46.7	2.1	<.01	0.4	1.3
Henke et al²³	NA	12.3	Control	11	11	0
		10.9	Epoetin 1	19	19	450
		11.4	Epoetin 2	14	14	900
Quirt et al²⁶	NA	10.7^4-159	Control	28	27	0		29.6			0.7
		10.9^4-159	Epoetin	28	27	450	900	14.8	NS^4-154	14.8	0.2
ten Bokkel Huinink et al²⁵	9.7	11.8^‡	Control	34	33	0		39.4			1.2		0.2
ten Bokkel Huinink et al²⁵	9.7	12.0^‡	Epoetin 1	46	45	450	225	4.4	^4-153	35.0	0.3		0.1	0.1
		11.6^‡	Epoetin 2	42	42	900	450	14.3	^4-153	25.1	0.4		0.1	0.1
Mean/median baseline Hb no lower than 12 g/dL, adult patients
Gamucci et al⁶³	NA	12.7	Control	17	17	0
		12.2	Epoetin	21	21	450
Sweeney et al⁶²	NA	10.7	Control	24	24	0
		12.1	Epoetin	24	22	1000	500
Del Mastro et al⁶⁴	8.0	13.1	Control	31	31	0		6.5
Del Mastro et al⁶⁴	8.0	13	Epoetin	31	31	450		0	NS^4-154	6.5
Thatcher et al²⁷	8.5	13.4^‡	Control	44	44	0		59.1			6.1		0.9
	8.6	13.7^‡	Epoetin 1	42	42	450	225	45.2	<.05	13.9	3.8	< .01	0.6	0.3
	8.0	13.6^‡	Epoetin 2	44	44	900	450	20.5	<.001	38.6	2.1	< .001	0.3	0.6
Welch et al⁶⁵	8.5	12.8	Control	15	15	0		53.3			5.4
	8.3	13	Epoetin	15	15	900	450	26.7	NS	26.6	4.0	NS

“Higher quality” trials in bold font; nonrandomized studies in italics. Data from Seidenfeld et al.3 ^(Tab16)

RBC indicates red blood cell; and NS, not statistically significant.

F4-150

A single entry is the transfusion trigger; multiple entries are mean Hb levels at transfusion.

F4-151

Mean/median Hb level at baseline not specified, but enrollment limited to patients with Hb ≤ 10 g/dL.

‡

The report provided only a median value, not a mean.

F4-153

Calculated odds ratio for transfusion suggests a significant difference, as upper limit of 95% CI is less than 1.0 (see “Meta-analysis”).

F4-155

Measured from day 28 to end of study.

F4-154

Calculated odds ratio for transfusion suggests no significant difference, as upper limit of 95% CI is less than 1.0 (see “Meta-analysis”).

F4-159

Did not specify whether reported value is mean or median.

View Large

This Feature Is Available To Subscribers Only